Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

Verhoeven, G. T.; Hegmans, J. P. J. J.; Mulder, P. G. H.; Bogoard, I. M.; Hoogsteden, H. C.; Prins, J. -B.
August 2002
Thorax;Aug2002, Vol. 57 Issue 8, p694
Academic Journal
Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPD patients with bronchial hyper-responsiveness (BHR). Methods: Twenty three patients with COPD were studied. Patients had to be persistent current smokers between 40 and 70 years of age. Non-specific BHR was defined as a PC20 for histamine of ⩽8 mg/ml. Patients received either 2 × 500 μg FP or placebo for 6 months. Expiratory volumes were measured at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from asymptomatic smokers served as controls. Results: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP. Forced expiratory volume in 1 second (FEV1) showed a steep decline in the placebo group but remained stable in patients treated with FP. FEV1/FVC, and maximal expiratory flows at 50% and 25% FYC (MEF50, MEF25) were significantly increased in the FP treated patients compared with the placebo group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+, CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of inflammation. Conclusion: In patients with COPD and BHR, FP has a positive effect on indices of lung function com- pared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally reduced.


Related Articles

  • Inhaled cortico-steroids and COPD exacerbations.  // Infectious Disease Alert;Apr2010 Primary Care, p8 

    The article discusses research done by R. Agarwal and colleagues on inhaled corticosteroids versus placebo for preventing chronic obstructive pulmonary disease (COPD) exacerbations, published in a 2010 issue of "Chest."

  • The Role of Corticosteroids in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Novak, Barbara // Critical Care Nurse;Oct2002, Vol. 22 Issue 5, p80 

    Presents information on a study that demonstrated that an 8-week course of steroids was just as effective as a 2-week course for chronic obstructive pulmonary disease (COPD) exacerbation treatment. Factors associated with the hospitalizations for COPD exacerbations; Drugs in the treatment of...

  • Long-Acting β2-Agonists in Asthma: Not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Inhaled corticosteroids and COPD exacerbations.  // Clinical Cardiology Alert;Apr2010 Primary Care Supplement, Vol. 15 Issue 4, p8 

    The article discusses research on the effectiveness of inhaled corticosteriods compared with placebo in preventing chronic obstructive pulmonary disease (COPD) exacerbations by R. Agarwal and colleagues published in a 2010 issue of "Chest."

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // Clinical Oncology Alert;Apr2007 Pharmacology Watch, p1 

    The article discusses two studies which have looked at the effects of various inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). According to a study that was published in the February 22, 2007 issue of "New England Journal of Medicine," the mortality...

  • Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Neurology Alert;Apr2010 Pharmacology, p8 

    The article discusses research on using placebo and inhaled corticosteroids (ICS) for the prevention of chronic obstructive pulmonary disorder (COPD) exacerbations, concluding that there is an increased risk of pneumonia among patients with COPD who were given ICS.

  • Mild persistent asthma and inhaled corticosteroids: is daily therapy really necessary? Bauchner, Howard // Archives of Disease in Childhood;Oct2005, Vol. 90 Issue 10, p1094 

    This article cites a study on the treatment of mild persistent asthma, which was published in the May 6, 2005 issue of the "Journal Watch Pediatrics and Adolescent Medicine." In this double-blind trial, researchers randomized 225 adults with mild persistent asthma to receive twice-daily inhaled...

  • Combination therapy 'best for COPD patients'. Polak, Monika // GP: General Practitioner;12/1/2003, p13 

    Combination therapy may be the best option for patients who have severe COPD, according to a Great Britain-led study. The results showed that the time to the first exacerbation among patients who were treated with an inhaled corticosteroid in combination with a long-acting beta-2 agonist was...

  • Analysis. Summerton, Nick // Update;5/19/2005, Vol. 70 Issue 5, p26 

    This article presents a study to find out whether intermittent as-needed corticosteroid treatment for mild persistent asthma equivalent to regular daily treatment. Treatment with daily or intermittent corticosteroid therapy in a six-centre randomised controlled trial was conducted. After...


Read the Article


Sign out of this library

Other Topics